Although the exact roles of these genes in NEPC development remain to be elucidated, some of them (i.e., TTN, MUC16, and KMT2D) are reportedly associated with disease progression and treatment resistance in prostate adenocarcinoma and other types of cancers.33, 34, 35, 36, 37, 38, 39. This evidence concerns the gene TTN and prostate adenocarcinoma.